ライフサイエンスコーパス: neuromuscular blockade

1 ria and PaO2/FIO2 less than 150 who received neuromuscular blockade.

2 iratory distress syndrome patients receiving neuromuscular blockade.

3 ients with PaO2/FIO2 less than 150 receiving neuromuscular blockade.

4 which is abolished by dorsal rhizotomy or by neuromuscular blockade.

5 rapy can be delivered without the need for a neuromuscular blockade.

6 x of whom required a subsequent surgery with neuromuscular blockade.

7 ble of rapid reversal of profound rocuronium neuromuscular blockade.

8 several years to control blood pressure and neuromuscular blockade.

9 ays patients received sedatives, opioids, or neuromuscular blockade.

10 tulism, which is characterized by peripheral neuromuscular blockade.

11 ere was no difference in MEE with or without neuromuscular blockade.

12 n with severe lung disease or in those under neuromuscular blockade.

13 renic nerve-hemidiaphragm from toxin-induced neuromuscular blockade.

14 ent; 2) Do phenotypes respond differently to neuromuscular blockade?

15 oreal membrane oxygenation patients received neuromuscular blockade (46%) or were heavily sedated wit

16 tists must balance the potential benefits of neuromuscular blockade against the increased risk of pos

17 ccinylcholine arguably remains the preferred neuromuscular blockade agent for rapid sequence intubati

18 pon the clinical scenario, and the choice of neuromuscular blockade agent.

19 on, acute associated nonpulmonary infection, neuromuscular blockade agents or nitric oxide use, bicar

20 Neuromuscular blockade alone does not cause hypothermia

21 With neuromuscular blockade and artificial ventilation, effer

22 stal nerves of T9 or T10 in adult rats, with neuromuscular blockade and artificial ventilation, under

23 e prevalence of neuromuscular weakness after neuromuscular blockade and of the costs to the healthcar

24 more severely hypoxaemic patients with ARDS, neuromuscular blockade and prone positioning have furthe

25 lly, methods to avoid entirely, or minimize, neuromuscular blockade and sedation are supported by rec

26 We wished to show that HO can occur after neuromuscular blockade and that these cases might provid

27 symptoms between the group that had received neuromuscular blockade and those who had not.

28 or to a usual-care approach without routine neuromuscular blockade and with lighter sedation targets

29 mentation, carbohydrate loading, reversal of neuromuscular blockade, and bowel preparation.

30 associated with higher PEEP, greater use of neuromuscular blockade, and prone positioning.

31 ong ICU variables (days of sedation, days of neuromuscular blockade, and severity of illness as measu

32 y distress syndrome receiving treatment with neuromuscular blockade because they cannot shiver.

33 as no difference in the need for sedation or neuromuscular blockade between the two tidal volume prot

34 be a useful tool for monitoring the depth of neuromuscular blockade but only if it is incorporated in

35 To investigate whether partial neuromuscular blockade can facilitate lung-protective ve

36 ient uncovered) or active (cooling blankets, neuromuscular blockade) cooling measures were used to ma

37 x adjunctive therapies for PARDS: continuous neuromuscular blockade, corticosteroids, inhaled nitric

38 ce of food from a narrow food well, when the neuromuscular blockade dissipated (by week 10) and in ma

39 operative glucose evaluation and management, neuromuscular blockade documentation, ventilator managem

40 Traditionally, reversal of neuromuscular blockade during anaesthesia was achieved b

41 nts offer a new approach for the reversal of neuromuscular blockade: encapsulation of the neuromuscul

42 Partial neuromuscular blockade facilitates lung-protective venti

43 gated as a means of limiting the duration of neuromuscular blockade following rapid sequence inductio

44 nuous infusion of doxacurium provides stable neuromuscular blockade for neurosurgical patients with t

45 6-37.3 degrees C), and fever occurred during neuromuscular blockade in 30 of 58 retrospective patient

46 A proposed mechanism of benefit of neuromuscular blockade in acute respiratory distress syn

47 Eleven days of mechanical ventilation and neuromuscular blockade in healthy baboons resulted in no

48 in of four alone for monitoring the depth of neuromuscular blockade in patients receiving continuous

49 degree of shivering) to assess the degree of neuromuscular blockade in patients undergoing therapeuti

50 The benefits of early continuous neuromuscular blockade in patients with acute respirator

51 Neuromuscular blockade in the setting of ARDS appears to

52 Partial neuromuscular blockade increased heart rate, mean arteri

53 s severe hypoxemia (i.e., prone positioning, neuromuscular blockade, inhaled pulmonary vasodilators)

54 1) We make no recommendation as to whether neuromuscular blockade is beneficial or harmful when use

55 plete recovery from both normal and profound neuromuscular blockade is now possible.

56 ine use of quantitative monitors of depth of neuromuscular blockade is the best guarantee of the adeq

57 Neuromuscular blockade (NMB) reversal with neostigmine a

58 and may derive greater clinical benefit from neuromuscular blockade (NMB).

59 , 2.47; 95% confidence interval, 1.47-4.14), neuromuscular blockade (odds ratio, 4.98; 95% confidence

60 of sedation (p = .007), but not with days of neuromuscular blockade or initial severity of illness.

61 alysis of the Reevaluation of Systemic Early Neuromuscular Blockade, or ROSE, trial.

62 vel, and tracheal intubations without use of neuromuscular blockade (p < 0.001).

63 ser to threshold) during exercise by partial neuromuscular blockade (P < 0.05).

64 with days of sedation (p = .006) and days of neuromuscular blockade (p = .035), but not with initial

65 the protocol was repeated following partial neuromuscular blockade (PNB; i.v. cisatracurium).

66 can be managed with early short-term use of neuromuscular blockade, prone position ventilation, or e

67 ntilation, spontaneous breathing trials, and neuromuscular blockade, respectively).

68 elerating the time to single innervation and neuromuscular blockade retarding it.

69 ACURASYS] and Reevaluation of Systemic Early Neuromuscular Blockade [ROSE]) presented equivocal evide

70 ry visual cortex of anaesthetized cats under neuromuscular blockade, that contrast invariance occurs

71 ision of continuous analgesia, sedation, and neuromuscular blockade to critically ill patients requir

72 4) We make no recommendation on the use of neuromuscular blockade to improve the accuracy of intrav

73 : control (no intervention) and with partial neuromuscular blockade (to increase central command infl

74 In the ROSE (Reevaluation of Systemic Early Neuromuscular Blockade) trial of cisatracurium in modera

75 Patients with intermittent neuromuscular blockade use (n = 4) had higher FIO2 (0.65

76 on (odds ratio, 1.07, 95% CI, 0.90-1.26), or neuromuscular blockade use (odds ratio, 0.95; 95% CI, 0.

77 Use of prone positioning and neuromuscular blockade was significantly more common in

78 Continuous neuromuscular blockade was the most common, used in 31%,

79 Onset, maintenance, and recovery of neuromuscular blockade were measured, using transcutaneo

80 Deeper sedation and intermittent neuromuscular blockade were used for patients with great

81 ctors (tracheal intubation method and use of neuromuscular blockade) were recorded.

82 weakness after continuous, nondepolarizing, neuromuscular blockade with a group of controls without

83 cardiac arrest followed asphyxia produced by neuromuscular blockade with and without airway obstructi

84 ine and prone positions in 30 patients under neuromuscular blockade with lung disorders including mod

85 ive drugs should be used prior to and during neuromuscular blockade, with the goal of achieving deep

86 ntrol static and dynamic exercise by partial neuromuscular blockade without alterations in gain (P <